Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,765 across all filing types
Latest filing 2022-09-27 Capital/Financing Update
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Torrent Pharma to acquire Curatio Healthcare
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Torrent Pharmaceuticals' acquisition of Curatio Healthcare. It includes details about the transaction, strategic rationale, and financial figures related to the acquisition. It also mentions a teleconference call to discuss the acquisition. There are no financial statements, quarterly or annual results, or detailed management analysis. The document is an announcement of a capital transaction (acquisition) rather than a full report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2022-09-27 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Torrent Pharmaceuticals' acquisition of Curatio Healthcare. It includes details about the transaction, strategic rationale, financial figures related to the acquisition, and mentions a teleconference call to discuss the acquisition. There are no financial statements or comprehensive financial reports included. The document is an announcement of a capital transaction (acquisition) rather than a full merger filing or detailed financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes including acquisitions.
2022-09-27 English
Acquisition
M&A Activity Classification · 100% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) disclosing the execution of definitive agreements for the acquisition of 100% stake in Curatio Health Care (I) Private Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating it is a regulatory disclosure. The content details the acquisition terms, target entity information, consideration, and strategic rationale. There are no financial statements or detailed financial analysis present, and the document is an announcement of a transaction rather than a full report. This fits the category of M&A Activity (TAR) filings, which cover announcements related to merger proposals or takeover bids.
2022-09-27 English
Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
M&A Activity Classification · 95% confidence The document is a formal letter addressed to the stock exchange (BSE Limited) regarding the execution of definitive agreements for the acquisition of 100% stake in Curatio Health Care (I) Private Limited by Torrent Pharmaceuticals Limited. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, indicating it is a regulatory disclosure. The content details the acquisition terms, target entity information, consideration, and strategic rationale. There are no financial statements or detailed financial performance data presented, nor is this a full report or earnings release. The document is an announcement of a significant corporate transaction (acquisition). According to the filing definitions, announcements related to merger proposals or takeover bids fall under M&A Activity (Code: TAR). The document is about acquisition agreements and fits the M&A Activity category with high confidence.
2022-09-27 English
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a short letter dated 17th September 2022 addressed to the BSE Limited listing department. It informs about the schedule of an investor meeting (Annual Global Investor Conference) on September 19, 2022. The letter references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The document does not contain any financial data, results, or detailed report content. It is an announcement of an upcoming investor meeting rather than a report or transcript. The document length is only 1411 characters, indicating it is a brief notice. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under SEBI regulations, not as an investor presentation or report itself.
2022-09-17 English
Schedule of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 95% confidence The document is a short letter dated 17th September 2022 addressed to the BSE Limited listing department. It informs about the schedule of an investor meeting (Annual Global Investor Conference) on September 19, 2022. The letter references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information. The document does not contain any financial data, results, or detailed report content. It is an announcement of an upcoming investor meeting rather than the meeting materials or transcript itself. The document length is only 1411 characters, indicating it is a brief notice. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure, not as an investor presentation or report.
2022-09-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.